Gamma-2 Herpesviruses as Vaccine Vectors for AIDS
$240,000R01FY2013AINIH
Harvard Medical School, Boston MA
Investigators
Linked publications & trials
Paper 31118261Paper 30541854Paper 28592531Paper 24899181Paper 23696734Paper 21900170Paper 21613403Paper 20172576Paper 18480451Paper 17451774Paper 16557291Paper 16537632Paper 16415030
Abstract
DESCRIPTION (provided by applicant): Results of both monkey and human trials have highlighted the difficulties in achieving vaccine protection against SIV and HIV. Persistent, recombinant herpes viruses are being used in monkeys to try to match the degree of protection that can be achieved with live attenuated strains of SIV. Results to date have been promising but the absence of anti-Env antibody responses from the recombinant herpes viruses has been a glaring deficiency. The proposed experiments will overcome this deficiency and allow full testing of the promise of this approach.
View original record on NIH RePORTER →